ADHD Prescriptions Increase 24.5 Percent After Aussie Coverage
This article was originally published in PharmAsia News
Executive Summary
Australian authorities report prescriptions for drugs to treat attention deficit hyperactivity disorder rose by 24.5 percent after the Pharmaceutical Benefits Scheme decided to cover the drugs. Alza's Concerta (methyphenidate hydrochloride), a long-acting stimulate, and Eli Lilly's Strattera (atomoxetine hydrochloride), a non-stimulant, were put on the PBS formulary after the agency decided to cover ADHD beginning last April. The cost of Concerta to patients dropped 80 percent as a result. But the government is about to release the results of a review of the advisability of covering the drugs in the wake of questions raised about the amount of psychiatric drugs prescribed for children. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.